Mibg (123i) Curium Netherlands

Iobenguane Sulfate I-123, the active ingredient in Mibg (123i) Curium Netherlands, is a radiopharmaceutical presented as an injectable solution for intravenous use. It is employed in diagnostic imaging to assess sympathetic nervous system activity, particularly in neuroendocrine and cardiac evaluations.

GNH USA supplies Mibg (123i) Curium Netherlands as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to global quality standards and provides reliable logistics for radiopharmaceuticals to oncology centres, nuclear medicine departments and imaging facilities across multiple regions.

Iobenguane Sulfate I-123 is used in diagnostic imaging of adrenergic tissue and related disorders. - Pheochromocytoma: enables scintigraphic localization of catecholamine‑producing tumors. - Neuroblastoma: assists in staging and treatment planning by visualizing tumor uptake. - Cardiac sympathetic innervation: assesses myocardial sympathetic nerve integrity for risk stratification.

Adverse reactions may occur following intravenous administration of Iobenguane Sulfate I-123.

Common Side Effects: - Nausea: mild, transient feeling of stomach upset. - Flushing: temporary reddening of the skin. - Headache: mild to moderate intensity. - Transient hypertension: short‑lived increase in blood pressure. - Injection site pain: mild discomfort at the venipuncture site. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure. - Radiation‑induced tissue injury: localized damage at high cumulative doses. - Cardiac arrhythmia: irregular heart rhythm potentially life‑threatening. - Pulmonary edema: fluid accumulation in the lungs. - Thyroid dysfunction: abnormal thyroid hormone levels due to iodine exposure.

Prior to use, clinicians should evaluate specific safety considerations. - Pregnancy: avoid unless the diagnostic benefit outweighs potential fetal radiation risk. - Breastfeeding: discontinue nursing or ensure adequate iodine blockade if continuation is necessary. - Renal impairment: assess renal function as reduced clearance may increase radiation exposure. - Thyroid blocking: consider administering stable iodine to reduce thyroid uptake of free iodine. - Radiation safety: follow ALARA principles to protect staff and other patients. - Store at ambient temperature: keep in original lead‑shielded container, protect from light, do not freeze.

Iobenguane Sulfate I-123 may interact with other agents that affect sympathetic imaging.

Major Interactions (Avoid): - Concurrent radiopharmaceuticals: can interfere with image interpretation. - Beta‑blockers: may diminish tracer uptake in adrenergic tissue. - Iodine‑containing contrast agents: may alter biodistribution of free iodine.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: monitor for blood pressure fluctuations during imaging. - Chemotherapeutic agents affecting norepinephrine transporters: observe potential changes in tracer localization. - Sympathomimetic agents: may increase background activity and affect image quality.